ImmuneInjectableResearch Protocol

LL-37 Dosage Chart

LL-37 is the active peptide of the only human cathelicidin, studied for broad antimicrobial activity and immunomodulatory signaling (Vandamme et al., 2012). Research explores both localized and systemic subcutaneous administration.

AI-built tool. Cross-check critical values against authoritative sources before use.

Half-life

Short (rapidly cleared systemically)

Format

Injectable

Purity

≥98%

Protocols

3 variants

Buy LL-37 — 50% off code ENHANCED View protocols

Research Protocols

Dosage Protocols

Each row reflects a common research protocol variant. These are reference ranges derived from published literature and community research — not medical guidance.

Protocol 1

Standard Research Protocol

2-4 weeks

Dose

100-250mcg once daily

Duration

2-4 weeks

Conservative systemic research range. Short courses are typical given LL-37's potency and dose-dependent cell effects.

Protocol 2

Localized Research Protocol

As studied

Dose

100mcg near the site of interest

Duration

As studied

Localized administration is used in wound and tissue research contexts. Keep total daily exposure low.

Protocol 3

Maintenance Protocol

Ongoing (cycled)

Dose

100mcg every other day

Duration

Ongoing (cycled)

Reduced-frequency dosing after an initial phase.

Mixing Math

Reconstitution

Reference values for preparing a research vial. Adjust the syringe reading if you change the water volume.

Vial size

10mg vial

BAC water

2ml bacteriostatic water

Concentration

5mg/ml (5000mcg/ml)

Dose / ml

100mcg = 0.02ml · 250mcg = 0.05ml

Syringe units

2 IU (100mcg) · 5 IU (250mcg) on a U-100 syringe

Need help converting different vial sizes? Use our reconstitution calculator to generate protocol-specific numbers instantly.

Frequently Paired

Common Stacks

Peptide

KPV

View guide

Peptide

BPC-157

View guide

Storage

Handling Notes

Lyophilized: 2-8°C preferred, -20°C for extended storage. Reconstituted: refrigerate at 2-8°C and use within about 28 days. Protect from light.

Research Considerations

Cautions

LL-37 is a research compound not approved for human use. Source only COA-verified material.
LL-37 shows dose-dependent cytotoxicity at higher concentrations in cell studies; higher is not better.
Immunomodulatory effects are complex and context-dependent; there is no established therapeutic dose.

Ready to start your research

Get LL-37 from Ascension Peptides

COA-verified, US-based, discreet shipping. Use code ENHANCED for 50% off your entire order.

Buy LL-37 now

Research use only. Not medical advice. Browse all dosage charts